Tumors Clinical Trial
Official title:
A Phase I, Open-label, Dose-escalation Study to Determine the Maximum Tolerance Dose (MTD) and to Evaluate the Safety of 188Re-BMEDA-liposome in Patient With Primary Solid Tumor in Advanced or Metastatic Stage.
This is a study to determine the maximum tolerance dose (MTD) and to evaluate the safety of 188Re-BMEDA-liposome in patient with primary solid tumor in advanced or metastatic stage.
Rhenium-188 is an ideal radionuclide for therapeutic use due to its maximum beta emission of 2.12MeV, short physical half-life of 16.9 hours, and its 155-keV gamma emission for imaging purposes. 188Re-BMEDA-liposome consists of 2 separate components (Rhenium-188 and liposome) and BMEDA as a linker. This study aims to find the MTD, evaluate the safety, efficacy profiles and investigate the biodistribution, radioactivity and radiation dosimetry of 188Re-BMEDA-liposome on primary solid tumor in metastatic stage patient by a single intravenous injection course. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Suspended |
NCT01562626 -
Phase I/II Study of APS001F With Flucytosine and Maltose in Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT00435669 -
A Phase I Study to Determine Absorption, Distribution, Metabolism, and Elimination of a Single Radiolabeled Dose of Brivanib (BMS-582664)
|
Phase 1 | |
| Completed |
NCT00400023 -
A Phase 1, Open-Label, Randomized, Cross-Over, Pharmacokinetic Study Evaluating the Effect of S-1 on Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT00410696 -
Pegfilgrastim Versus Filgrastim After High-dose Chemotherapy
|
Phase 2 | |
| Completed |
NCT00395434 -
Safety Study of Increasing Doses of Combretastatin in Combination With Bevacizumab (Avastin) in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT00375245 -
Rapamycin With Grapefruit Juice for Advanced Malignancies
|
Phase 1 | |
| Completed |
NCT00372437 -
A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine
|
Phase 1/Phase 2 | |
| Recruiting |
NCT00553033 -
Laparoscopic Liver Resection
|
N/A | |
| Completed |
NCT00248404 -
NB1011 Administered by Continuous Infusion in Cancers That Overexpress Thymidylate Synthase (TS)
|
Phase 1/Phase 2 | |
| Completed |
NCT00207103 -
MAD in Cancer Patients: Safety of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors
|
Phase 1 | |
| Completed |
NCT00222443 -
Pilot Study Combining Temozolomide, Oncovin, Camptosar and Oral Antibiotic in Children and Adolescents With Recurrent Malignancy
|
Phase 1 | |
| Terminated |
NCT03251924 -
A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05103969 -
Cohort of Tumors With POLE/D1 Mutation
|
||
| Completed |
NCT00446446 -
PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer)
|
Phase 2 | |
| Completed |
NCT02275910 -
Phase 1 Study of E7090 in Subjects With Solid Tumor
|
Phase 1 | |
| Completed |
NCT01448759 -
Evaluation of Plasma Alcohol Concentration in Patients Receiving Paclitaxel or Docetaxel
|
N/A | |
| Terminated |
NCT01081808 -
Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT00389480 -
Study of AR-67 (Formerly DB-67) in Adult Patients With Refractory or Metastatic Solid Malignancies
|
Phase 1 | |
| Completed |
NCT00398814 -
Phase I Study of Perifosine + Sorafenib for Patients With Advanced Cancers
|
Phase 1 | |
| Terminated |
NCT00130936 -
Study of Epirubicin (Pharmorubicin®), Carboplatin (Paraplatin®) and Capecitabine (Xeloda®) (ECC) in the Treatment of Unresectable Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer With Pharmacogenetic Correlates
|
Phase 1/Phase 2 |